Inhibitors of phosphatidic acid phosphohydrolase (PAP) enzymes for the treatment of cancers that depend on members of the ErbB/HER tyrosine kinase receptor family
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 24, 2016
Grant Date -
May 22, 2014
app pub date -
Feb 6, 2012
filing date -
Feb 8, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Compounds and combinations of them that inhibit phosphatidic phosphohydrolase (PAP) enzymatic activity are formulated into pharmaceuticals useful in cancer treatment. Inhibitors of PAP can be used for blocking the progression of cancers that depend on the epidermal growth factor receptor (EGFR), its oncogenic variants and other members of its ErbB tyrosine kinase receptor family, through induction of their endocytosis, thus making them inaccessible to the extracellular stimuli that promote maintenance and progression of cancer.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully